Etanercept, improved dosage schedules and combinations in the treatment of psoriasis: an update

Siegfried SegaertDepartment of Dermatology, University Hospital Leuven, BelgiumAbstract: Etanercept, a subcutaneously administered fully human soluble tumor necrosis factor (TNF) receptor, was initially approved for the treatment of psoriasis at a dose of 25 mg twice weekly in repeated 24-week cycle...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Siegfried Segaert
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/c3a4606f391a49e58df829dbcf40fbc6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c3a4606f391a49e58df829dbcf40fbc6
record_format	dspace
spelling	oai:doaj.org-article:c3a4606f391a49e58df829dbcf40fbc62021-12-02T06:33:15ZEtanercept, improved dosage schedules and combinations in the treatment of psoriasis: an update1178-7031https://doaj.org/article/c3a4606f391a49e58df829dbcf40fbc62009-08-01T00:00:00Zhttp://www.dovepress.com/etanercept-improved-dosage-schedules-and-combinations-in-the-treatment-a3430https://doaj.org/toc/1178-7031Siegfried SegaertDepartment of Dermatology, University Hospital Leuven, BelgiumAbstract: Etanercept, a subcutaneously administered fully human soluble tumor necrosis factor (TNF) receptor, was initially approved for the treatment of psoriasis at a dose of 25 mg twice weekly in repeated 24-week cycles with the possibility to double the dose in the first 12 weeks of the first cycle. During intermittent treatment, patients retain their ability to respond to etanercept. Recently, a new dosing schedule of etanercept 50 mg once weekly was approved, based on a study in which PASI-75 (75% improvement of Psoriasis Area and Severity Index) was achieved by 37% and 71% of patients at week 12 and 24. Another study demonstrated a PASI-75 of 57% and 69% in pediatric psoriasis patients receiving etanercept 0.8 mg/kg (up to 50 mg) once weekly for 12 and 24 weeks respectively, resulting in European approval from age 8. Based on recent clinical trials, the antipsoriatic effect of etanercept can be markedly increased in combination with acitretin, methotrexate or UVB. The combination with acitretin appears attractive because of its non-immunosuppressive and chemopreventive properties. Etanercept&ndash;methotrexate combination therapy is well established in rheumatologic patients. From a long-term perspective, the combination of TNF-inhibitors with phototherapy (photocarcinogenesis) or cyclosporine (carcinogenesis, infections) warrants great caution however. Finally, combination with topical calcipotriol&ndash;betamethasone ointment may increase the speed of response to TNF-inhibitors in the first 4 weeks of treatment.Keywords: etanercept, psoriasis, dosing schedules, combination therapy Siegfried SegaertDove Medical PressarticlePathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol 2009, Iss default, Pp 29-36 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Siegfried Segaert Etanercept, improved dosage schedules and combinations in the treatment of psoriasis: an update
description	Siegfried SegaertDepartment of Dermatology, University Hospital Leuven, BelgiumAbstract: Etanercept, a subcutaneously administered fully human soluble tumor necrosis factor (TNF) receptor, was initially approved for the treatment of psoriasis at a dose of 25 mg twice weekly in repeated 24-week cycles with the possibility to double the dose in the first 12 weeks of the first cycle. During intermittent treatment, patients retain their ability to respond to etanercept. Recently, a new dosing schedule of etanercept 50 mg once weekly was approved, based on a study in which PASI-75 (75% improvement of Psoriasis Area and Severity Index) was achieved by 37% and 71% of patients at week 12 and 24. Another study demonstrated a PASI-75 of 57% and 69% in pediatric psoriasis patients receiving etanercept 0.8 mg/kg (up to 50 mg) once weekly for 12 and 24 weeks respectively, resulting in European approval from age 8. Based on recent clinical trials, the antipsoriatic effect of etanercept can be markedly increased in combination with acitretin, methotrexate or UVB. The combination with acitretin appears attractive because of its non-immunosuppressive and chemopreventive properties. Etanercept&ndash;methotrexate combination therapy is well established in rheumatologic patients. From a long-term perspective, the combination of TNF-inhibitors with phototherapy (photocarcinogenesis) or cyclosporine (carcinogenesis, infections) warrants great caution however. Finally, combination with topical calcipotriol&ndash;betamethasone ointment may increase the speed of response to TNF-inhibitors in the first 4 weeks of treatment.Keywords: etanercept, psoriasis, dosing schedules, combination therapy
format	article
author	Siegfried Segaert
author_facet	Siegfried Segaert
author_sort	Siegfried Segaert
title	Etanercept, improved dosage schedules and combinations in the treatment of psoriasis: an update
title_short	Etanercept, improved dosage schedules and combinations in the treatment of psoriasis: an update
title_full	Etanercept, improved dosage schedules and combinations in the treatment of psoriasis: an update
title_fullStr	Etanercept, improved dosage schedules and combinations in the treatment of psoriasis: an update
title_full_unstemmed	Etanercept, improved dosage schedules and combinations in the treatment of psoriasis: an update
title_sort	etanercept, improved dosage schedules and combinations in the treatment of psoriasis: an update
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/c3a4606f391a49e58df829dbcf40fbc6
work_keys_str_mv	AT siegfriedsegaert etanerceptimproveddosageschedulesandcombinationsinthetreatmentofpsoriasisanupdate
_version_	1718399898787774464

Etanercept, improved dosage schedules and combinations in the treatment of psoriasis: an update

Ejemplares similares